Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Q2 2022 revenue of $15.5 million, Adjusted EBITDA of $6.2 million and cash from operations of $3.5 million. Total Vascepa prescriptions grew 88% year-over-year, reflecting sequential growth of...
Reimbursement coverage for Vascepa in Canada is now approximately 70% for publicly covered lives and private coverage is now in excess of 95% for those that are in-label Public reimbursement for...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2022 financial results on Thursday, August 11, 2022. The Company will hold a conference call...
Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in-label Public reimbursement for Vascepa is now...
New Brunswick, Northwest Territories and the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples will reimburse Vascepa for the reduction of cardiovascular risk in...